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Abstract
The aim of the present chapter is to characterize the management of anticoagulation in 
the real-world clinical setting, describing all pharmacological aspects of anticoagulant 
medications, in particular safety aspects. The chapter is structured into three main sec-
tions. Within the first two sections, active principles are classified on the basis of their 
pharmacological properties (pharmacodynamic and pharmacokinetic characteristic) in 
old and new molecules (or first and second generation class). In the third one, we dis-
cuss safety issues of anticoagulants using available data from postmarketing evidences. 
Furthermore, we also provide some essential information on the use of this kind of medi-
cations in special populations (i.e., elderly, coronary artery disease, diabetics, chronic 
kidney disease, etc.) in clinical practice.
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1. Introduction
Hemostasis is the physiologic process for the prevention of hemorrhage and bleeding in 
response to blood vessel damage, while physiologic inhibition of coagulation ensures the 
fluidity of blood. The ways in which these factors all balance each other can be the difference 
between hemostasis and thrombosis [1]. Alteration of this balance in favor of coagulation 
results in thrombosis, a pathological process characterized by the formation of a platelet or 
fibrin clot, which could occlude both arterial and venous vessels.
This chapter reviews the agents commonly used for controlling blood fluidity, including in 
particular:
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• The coumarin anticoagulants: warfarin, acenocumarol, and phenprocoumon;
• Direct oral anticoagulants (DOACs): dabigatran, rivaroxaban, apixaban, and edoxaban;
• Parenteral anticoagulant heparin and its derivatives.
2. Oral anticoagulants
2.1. Old agents
2.1.1. Warfarin
2.1.1.1. Mechanism of action
Warfarin is a racemic mixture of two optically active isomers, the R and S enantiomers, and 
it produces its anticoagulant effect by interfering with the cyclic interconversion of vitamin 
K and vitamin K-2,3-epoxide. Warfarin blocks vitamin K epoxide reductase (VKOR), and 
the consequent conversion of oxidized vitamin K epoxide into its reduced form, vitamin K 
hydroquinone [2]. However, warfarin also has a simultaneous procoagulant effect caused by 
blocking the activation of protein C and S, two endogenous anticoagulants. A rapid deple-
tion of these proteins leads to a transient hypercoagulable state in the first 1 or 2 days of 
therapy.
2.1.1.2. Indications
Warfarin is prescribed for the treatment and prophylaxis of various thromboembolic diseases 
such as atrial fibrillation (AF), deep venous thrombosis (DVT), transient ischemic attacks (TIA), 
pulmonary embolism, and other thromboembolic disorders that may affect carriers of cardiac 
valvular prosthesis or patients who underwent electric cardioversion [3, 4]. The dose-response 
relationship of warfarin is influenced by genetic and environmental factors, including muta-
tions in gene coding for cytochrome P (CYP) 450, the hepatic enzyme responsible for oxidative 
metabolism of warfarin, mutations in gene coding for VKOR [5], concomitant drugs, diet, 
and various disease states [6]. Although warfarin and other dicumarol derivatives cross the 
placenta and contribute to fetal bone and central nervous system abnormalities when mothers 
are treated with warfarin within the first-trimester of pregnancy, there is no evidence that war-
farin directly affects bone metabolism when administered to children or adults [7]. Women 
who will be managed with therapeutic anticoagulation in pregnancy should be treated prefer-
ably with a parenteral agent, such as heparin and low-molecular-weight heparin (LMWH), 
unfractionated heparin (UFH), and fondaparinux [8].
2.1.1.3. Pharmacokinetics
After oral intake, warfarin enantiomers are absorbed rapidly and almost completely from the 
gastrointestinal tract (100% of bioavailability) and reach their maximal plasma concentration 
in 90 minutes in healthy people. Racemic warfarin is extensively bound to plasma protein 
(mainly albumin, 99%) and has a plasma half-life of 36–42 hours [9]. Warfarin is extensively 
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metabolized in the liver by different CYP enzymes: CYP3A4 and CYP1A2 primarily metabo-
lize the R-enantiomer, whereas the S-enantiomer is mainly metabolized by CYP2C9. The inac-
tive metabolites are excreted with the urine and stool [10].
2.1.1.4. Interactions
Drug interactions that alter the pharmacokinetics of warfarin may include alterations in absorp-
tion (e.g., cholestyramine), which would decrease the anticoagulant effect. Reduced plasma-
binding because of the presence of excessively albumin-bound drugs causes an increase in free 
drug plasma concentration and therefore an increase in antithrombotic activity. Aspirin and 
other nonsteroidal anti-inflammatory drugs (NSAIDs), and large doses of penicillins inhibit 
platelet function, prolong bleeding time, and have the potential to increase the risk of warfarin-
associated bleeding, especially upper gastrointestinal bleeding due to their gastric erosion 
effect. Many drug interactions with warfarin are caused by alterations in metabolism either 
by CYP2C9 enzyme induction [11], which increases warfarin clearance and thereby reduc-
ing antithrombotic activity (e.g., phenytoin, rifampin) [12], or stereoselective and nonselec-
tive enzyme inhibition (e.g., amiodarone, cimetidine, sulfamethoxazole, metronidazole) [13], 
which increases its antithrombotic effect (and the INR). Amiodarone is a potent inhibitor of the 
metabolic clearance of both the S-enantiomer and the R-enantiomer and potentiates warfarin 
anticoagulation [14]. The anticoagulant effect of warfarin is augmented by second-generation 
and third-generation cephalosporins, which inhibit the cyclic interconversion of vitamin K, by 
thyroxine, which increases the metabolism of coagulation factors, by clofibrate and by acet-
aminophen, by inhibition of VKOR through a toxic metabolite of the drug [2]. The effect of 
statins or fibrates on the risk of bleeding in patients on VKAs is controversial. The initiation of a 
fibrate or statin that inhibits CYP3A4 enzymes was reported to increase the risk of gastrointes-
tinal bleeding, whereas statins that are mainly excreted unchanged were not found to be asso-
ciated with such an increased risk [15, 16]. Furthermore, nutritional supplements and herbal 
products are particularly problematic in warfarin-treated patients, who often fail to inform 
physicians and use these products as self-medication. Fluctuating levels of dietary vitamin K 
derive predominantly from phylloquinones in plant material, i.e., green tea and natto [17, 18].
2.1.1.5. Therapy management
Patients at low risk of thrombosis (i.e., AF) do not require heparin treatment at the beginning of 
warfarin therapy and a low initial dose regimen starting with 3 mg warfarin is recommended. 
The time taken to reach a therapeutic International Normalized Ratio (INR) is not critical; INR 
values should be monitored weekly on day 1 (baseline), day 8 and day 15, especially in older 
people who respond more slowly with changes to the INR. All patients who are sensitive to 
warfarin effects should monitor their INR more frequently (i.e., every 3–4 days). Patients at 
high risk of thrombosis (i.e., DVT) should be treated with heparin or LMWH when starting 
warfarin therapy for a minimum of 5 consecutive days. For initiation, a starting dose of 5 mg 
warfarin with daily INR monitoring for a minimum of 5 days is recommended. After day 4, 
clinicians should continue regular INR monitoring every 3 to 4 days until stabilized, and if 
the patient is still on heparin or LMWH, review the ongoing need for these additional anti-
coagulants. If INR values change of 0.5 over 3 days or 1.0 over 7 days, the INR is considered 
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unstable. After INR stabilization, clinicians should adopt a maintenance dosing. The weekly 
dose can be prescribed using a range of dosing regimens (i.e., alternate day dosing or dose 
regimens with different doses for weekdays compared to the weekend).
Dose modification should be taken into account following the INR monitoring:
• INR < 1.5: weekly dose should be increased by 20%;
• INR between 1.5 and 1.9: weekly dose should be increased by 10% only if the alteration of 
the values persists for more than a week;
• INR between 2 and 3: no change in dose regimen;
• INR between 3.1 and 3.9: weekly dose should be decreased by 10–20% only if the alteration 
of the values persists for more than a week;
• INR between 4 and 4.9: the patient has to omit one dose, decrease the weekly dose by 
10–20%, and monitor INR in 2–5 days.
For INR values greater than or equal to 5, there is a significantly increased risk of bleeding and 
vitamin K administration should be evaluated. Patients have to cease warfarin therapy and 
restart with a reduced dose, when INR is minor than 5 [19].
In case of switch to another anticoagulant agent and in particular to a direct oral anticoagu-
lant agents (DOACs) in patients with atrial fibrillation, INR should be strictly monitored. 
Apixaban and dabigatran should be started when INR < 2, rivaroxaban when INR < 3, and 
edoxaban when INR ≤ 2.5 [20].
2.1.1.6. Real-world safety aspects
Vitamin K antagonists reduce stroke and systemic embolism by 64% and all-cause mortality 
by 26%, compared to placebo in patients with atrial fibrillation [21]. However, as already 
mentioned above, VKAs have many drug and food interactions and require routine INR 
monitoring, and these limitations result in under-treatment for 30–50% of AF patients [22].
The CHADS2 scoring system [23] is a simple system that can be used to assess the annual risk of stroke in AF. In the CHADS2 scoring system, each point increases the annual risk of stroke by a factor of 1.5. Treatment with warfarin is recommended for a CHADS2 or CHA2DS2VASc scores of equal to or greater than 2. While the CHADS2 score is simple, it does not include many common stroke risk factors. The CHA2DS2VASc score is inclusive of the most common stroke risk factors in everyday clinical practice and has been validated in multiple cohorts; 
the accumulated evidence shows that CHA2DS2VASc is better at identifying “truly low-risk” patients with AF and is as good as, and possibly better than, scores such as CHADS2 in iden-tifying patients who develop stroke and thromboembolism [24]. Direct comparison between 
the effects of warfarin and aspirin has been undertaken in several studies, demonstrating 
that warfarin was significantly superior, with a relative risk (RR) reduction of stroke of 39%.
In clinical practice, the risk of stroke should be weighed against the risk of bleeding to assess appro-
priateness of anticoagulant therapy. Warfarin causes major bleedings in 1–2% of people treated and 
intracranial bleeding in 0.1–0.5% of patients each year of treatment [25]. The highest rate of major 
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bleeding occurs in the first 3 months of treatment [26]. In comparison, aspirin causes major bleed-
ing in 1.3% of patients [26]. Absolute risk increases for intracranial hemorrhage with warfarin com-
pared to aspirin is only 0.2% per year [27]. Risk of bleeding can be assessed using the HAS-BLED 
scoring system, where a bleeding risk score of equal to or greater than 3 indicates high risk. There 
are other bleeding risk assessment tools available including HEMORR2HAGES [23]. Assessment may identify reversible risks that can be managed prior to initiation of warfarin. In general, clini-
cians should be cautious and conduct regular review of the patient if initiating warfarin [24].
2.1.2. Acenocoumarol and phenprocoumon
Like warfarin, acenocoumarol and phenprocoumon also exist as optical isomers that have 
different stereochemical characteristics. R-acenocoumarol has an elimination half-life of 9 h; it 
is primarily metabolized by CYP2C9 and CYP2C19 and is more potent than S-acenocoumarol. 
In fact, S-acenocoumarol has a faster clearance (elimination half-life of 0.5 h), it is primarily 
metabolized by CYP2C9 and undergoes extensive first pass metabolism. The treatment dose 
may vary between patients up to 10-fold, ranging from 1 to 9 mg daily [28, 29].
Phenprocoumon is a much longer acting agent, with both the R- and the S-isomers with 
elimination half-lives of 5.5 days. Both are metabolized by CYP2C9, and S-phenprocoumon 
is 1.5–2.5 times more potent than R-phenprocoumon. It is administered in daily maintenance 
doses of 0.75–9 mg [29, 30].
As for warfarin, allelic variants of CYP2C9, CYP2C9*2, and CYP2C9*3 could lead to bleed-
ing complications, especially if they code for enzymes with approximately 12 and 5% of the 
enzymatic activity of the wild type genotype CYP2C9*1 [31].
2.2. Novel oral anticoagulants
2.2.1. Direct oral anticoagulants
Four non–vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants 
(DOACs), are widely used as alternatives to warfarin: dabigatran etexilate, rivaroxaban, 
apixaban, and edoxaban. In contrast with warfarin, DOACs have a more predictable thera-
peutic effect, do not require routine INR monitoring, and have fewer potential drug-drug 
interactions and no restriction on dietary consumption of vitamin K–containing food [32].
2.2.1.1. Mechanism of action
DOACs act through direct inhibition of thrombin or inhibition of activated factor X (factor 
Xa). Dabigatran etexilate mesylate is a competitive direct thrombin inhibitor. Rivaroxaban, 
apixaban, and edoxaban inhibit factor Xa and prothrombinase activity, thus inhibiting the 
conversion of prothrombin to thrombin and decreasing thrombus formation.
2.2.1.2. Indications
DOACs indications comprehend thromboembolic prevention in patients with nonvalvular atrial 
fibrillation (AF), DVT, and pulmonary embolism. For each one of these conditions, dose regimen 
has to be adjusted. Creatinine clearance (CrCl) values should be checked for dose management.
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2.2.1.3. Pharmacokinetics
Dabigatran etexilate has a bioavailability of 3–7%, and it is bound to plasma proteins for a 
total amount of 35%. Its plasma half-life ranges between 12 and 17 hours but increases to 
18–28 hours in case of mild to severe renal impairment. Dabigatran is converted into active 
dabigatran through hepatic and plasma hydrolysis and hepatic glucuronidation. Excretion 
occurs through the kidney after i.v. administration, while after oral administration, 7% of 
drug is recovered in urine and 86% is excreted in feces.
Rivaroxaban reaches the peak of plasma concentration in 2–4 hours, and its bioavailability 
ranges between 66% (20 mg) and 80–100% (10 mg); 92–95% of the drug administered is bound 
to plasma proteins for a total volume of distribution of 50 L. Hepatic oxidation by CYP3A4/5, 
CYP2J2, and hydrolysis converts rivaroxaban to inactive metabolites excreted through kidney 
(66%) and feces (28%).
Apixaban has a bioavailability of 50% and reaches plasma peak concentration in 3–4 hours. It 
is bound for 87% to plasmatic proteins, and it is metabolized by CYP3A4/5, 1A2, 2C9, 2C19, 
2 J2, O-demethylation, and hydroxylation in the liver. Excretion occurs through the kidney 
(27%) and intestinal and biliary tract.
Edoxaban reaches the peak of plasma concentration in 1–2 hours, has a bioavailability of 62%, 
and it is bound for 55% to plasma protein. Its plasma half-life ranges from 10 to 14 hours. 
Edoxaban is converted through CYP3A4, hydrolysis, conjugation, and oxidation. Metabolites 
are excreted through kidneys (50%) and biliary/intestinal excretion [33].
2.2.1.4. Interactions
All DOACs are substrate of P-glycoprotein (P-gp), and apixaban and rivaroxaban are sub-
strates for CYP3A4 metabolism. Thus, concomitant medications that are inducers or inhibitors 
of these pathways should be evaluated for potential interactions [34]. In particular, concomi-
tant use of rifampin (P-gp inducer), carbamazepine, phenytoin (both P-gp and CYP3A4 induc-
ers) and cyclosporine, ketoconazole, verapamil, and HIV protease inhibitors (both P-gp and 
CYP3A4 inhibitors) should be avoided or needs an adjustment of DOACs treatment [34, 35].
2.2.1.5. Therapy management
The main advantage of DOACs is a more rapid onset and offset of action that eliminates the 
necessity of routine INR monitoring. In case of acute care or perioperative settings, when 
there is uncertainty about the timing of last ingestion, renal function, and gastrointestinal 
absorption, there are several values that can be checked to assess DOACs effect, such as acti-
vated partial thromboplastin time (aPPT), prothrombin time (PT), and antifactor Xa activity. 
During rivaroxaban treatment renal function (CrCl), complete blood count (CBC) tests and 
hepatic function monitoring are required periodically, at least annually.
Dabigatran treatment of nonvalvular AF provides:
• 150 mg twice daily if CrCl>30 mL/min;
• 75 mg twice daily if CrCl is between 15 and 30 mL/min;
• 75 mg twice daily if CrCl is between 30 and 50 mL/min with concomitant P-gp inhibitors.
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Rivaroxaban is administered with the evening meal on the basis of CrCl values:
• 20 mg daily if CrCl<50 mL/min;
• 15 mg daily if CrCl is between 15 and 50 mL/min.
Apixaban is given at the dose of 5 mg twice daily in patients with nonvalvular AF and reduced 
to 2.5 mg twice daily if there are at least two of the following conditions: body weight ≤ 60 kg, 
creatinine ≥ 1.5 mg/dL, age ≥ 80 years. Apixaban is not recommended in case of severe hepatic 
impairment.
Edoxaban is administered on the basis of CrCl:
• 60 mg daily if CrCl is between 50 and 95 mL/min;
• 30 mg daily if CrCl is between 15 and 50 mL/min.
2.2.1.6. Real-world safety aspects
2.2.1.6.1. Dabigatran
A systematic review and meta-analysis was performed with the aim of summarizing all 
available evidence from high-quality real-world observational studies regarding efficacy 
and safety of non–vitamin-K oral anticoagulants compared with vitamin-K antagonists 
in patients with atrial fibrillation [36]. Compared with warfarin, dabigatran is associ-
ated with lower risk for intracranial hemorrhage in several studies that included 606.855 
patients (hazard ratio (HR), 0.42; 95% confidence interval (CI), 0.37–0.49) and lower risk 
for death in 319.486 patients (HR, 0.63; 95% CI, 0.52–0.76). There is no statistical difference 
between dabigatran and warfarin for the outcomes of ischemic strokes (HR, 0.96; 95% CI, 
0.80–1.16); ischemic stroke or systemic embolism (HR, 1.17; 95% CI, 0.92–1.50); any stroke 
or systemic embolism (HR, 0.93; 95% CI, 0.77–1.14); major hemorrhage (HR, 0.83; 95% 
CI, 0.65–1.05); and myocardial infarction (HR, 0.96; 95% CI, 0.77–1.21). Authors identified 
10 studies that included 537.770 patients which assessed the outcome of gastrointestinal 
hemorrhage and reported higher risk of dabigatran compared with warfarin (HR, 1.20; 
95% CI, 1.06–1.36). Authors also reported the presence of a significant heterogeneity in all 
analyses with the exception of the outcome of intracranial hemorrhage and any stroke or 
systemic embolism.
2.2.1.6.2. Rivaroxaban
As reported in the study authored by Ntaios and Colleagues [36], compared with warfarin, 
rivaroxaban is associated with lower risk for intracranial hemorrhage in several real-world 
studies that included 136,221 patients (HR, 0.64; 95% CI, 0.47–0.86). There is no statistical dif-
ference between rivaroxaban and warfarin for the outcomes of ischemic stroke (HR, 0.89; 95% 
CI, 0.76–1.04); ischemic stroke or systemic embolism (HR, 0.73; 95% CI, 0.52–1.04); any stroke 
or systemic embolism (HR, 0.87; 95% CI, 0.71–1.07); major hemorrhage (HR, 1.00; 95% CI, 
0.92–1.08); myocardial infarction (HR, 1.02; 95% CI, 0.54–1.89); and death (HR, 0.67; 95% CI, 
0.35–1.30). Authors identified four studies that included 71.368 patients which assessed the 
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outcome of gastrointestinal hemorrhage and reported higher risk of rivaroxaban compared 
with warfarin (HR, 1.24; 95% CI, 1.08–1.41). Authors reported a significant heterogeneity for 
the outcomes of intracranial hemorrhage and death.
2.2.1.6.3. Apixaban
Compared with warfarin, apixaban is associated with lower risk for intracranial hemorrhage 
in several real-world studies that included 66.482 patients (HR, 0.45; 95% CI, 0.31–0.63); lower 
risk for gastrointestinal hemorrhage in 2 studies that included 33.323 patients (HR, 0.63; 95% 
CI, 0.42–0.95); and lower risk for major hemorrhage in 4 studies that included 89.036 patients 
(HR, 0.55; 95% CI, 0.48–0.63) [36]. Authors identified only one study of 41.785 patients which 
assessed death; it reported lower risk with apixaban compared with warfarin (HR, 0.65; 95% 
CI, 0.56–0.75). Also, they identified only one study of 15.390 patients which assessed the 
outcome of any stroke or systemic embolism; it reported lower risk of apixaban compared 
with warfarin (HR, 0.67; 95% CI, 0.46–0.98). There is neither a statistical difference between 
apixaban and warfarin for the outcomes of ischemic stroke (HR, 0.95; 95% CI, 0.75–1.19) nor 
for ischemic stroke or systemic embolism (HR, 1.07; 95% CI, 0.87–1.31). Authors reported a 
significant degree of heterogeneity in the analysis of the outcomes of gastrointestinal hemor-
rhage but not for the other outcomes.
2.2.2. Betrixaban
Betrixaban is an oral factor Xa inhibitor whose extended duration treatment reduced 
a composite of asymptomatic DVT, symptomatic DVT, nonfatal PE, and venous throm-
boembolism (VTE)–related death compared to enoxaparin, without an increase in major 
bleeding [37]. It acts by competitively binding to the active site of Xa, preventing its abil-
ity to convert prothrombin to thrombin. Betrixaban is rapidly absorbed with mean peak 
concentrations occurring within 3–4 hours after oral administration. Excretion is mostly 
unchanged through the bile with renal excretion accounting for 5–7% of the orally admin-
istered dose. Betrixaban is not a substrate for major cytochrome P450 enzymes, but it is a 
substrate for P-gp. Potent inhibitors of P-gp (i.e., ketoconazole, amiodarone, and diltiazem) 
increase betrixaban concentrations around twofold [38]. A recent network meta-analysis 
aimed to comprehensively analyze the thromboprophylactic drugs that are used to prevent 
thrombosis and reduce bleeding risk. Results showed that sudoxicam, FXI-ASO (factor 
XI antisense oligonucleotide), and betrixaban were likely to be associated with the lowest 
risk of all-cause bleeding after major joint surgery. Furthermore, betrixaban, dalteparin, 
and warfarin were associated with the lowest risk of major bleeding/nonmajor clinically 
relevant bleeding events [39].
The FDA (Food and Drug Administration) approved betrixaban on June 2017 for the pro-
phylaxis of VTE in adult patients hospitalized for an acute medical illness, who are at risk 
for thromboembolic complications due to moderate or severe restricted mobility and other 
risk factors for VTE. The recommended dose of betrixaban is an initial single dose of 160 mg 
starting on day 1, followed by 80 mg once daily taken for 35–42 days at the same time each 
day with food. Dose should be reduced in case of severe renal and hepatic impairment or 
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concomitant treatment with P-gp inhibitors. The most common adverse reactions (≥5%), 
observed in the APEX trial considered for approval, were related to bleeding.
2.2.3. Sulodexide
Sulodexide belongs to a class of substances known as glycosaminoglycans (GAGs), composed 
of a fast-moving heparin fraction (80%) with affinity for antithrombin III and a dermatan 
sulfate fraction (20%) with affinity for heparin cofactor II.
2.2.3.1. Mechanism of action
Sulodexide exerts a strong antithrombotic activity by simultaneously potentiating the anti-
protease activities of both antithrombin III and heparin cofactor II. Sulodexide also has a 
profibrinolytic effect (through activation of tissue plasminogen activator and inhibition of 
plasminogen activator inhibitor), an antiproliferative effect on smooth muscle cells, and anti-
lipemic and antiatherosclerotic effects [40, 41].
2.2.3.2. Indications
Several clinical studies have demonstrated the efficacy of sulodexide in the treatment or preven-
tion of vascular diseases associated with increased thrombotic risk, such as peripheral arterial 
occlusive diseases, post-myocardial infarction, recurrent DVT, and postthrombotic syndrome 
[42]. Other clinical applications are treatment of venous ulcers, cerebrovascular disorders, dia-
betic nephropathy, and other diabetic complications (nephropathy and macular edema).
2.2.3.3. Pharmacokinetics
Sulodexide is available for both intravenous and intramuscular administration, but it can be 
taken also orally. By the oral route, Sulodexide is absorbed within 1–2 hours and behaves 
as a mono-compound, reaching the time to peak in about 4 hours with a dose of 50–100 mg. 
Similar concentrations are maintained at least up to 18 hours. The distribution volume is very 
large, due to a higher affinity of sulodexide for the extensive surface area of the endothelium 
rather than for plasma proteins. Metabolism is liver dependent and based on N-desulfation, 
while excretion is mostly kidney dependent [40, 43].
2.2.3.4. Therapy management
Nowadays, sulodexide 250 LSU (lipasemic unit) capsules or 600 LSU parenteral preparation 
is approved only in Europe (Italy) for venous chronic ulcers in adults (250 LSU twice daily, 
away from meals).
2.2.3.5. Safety
Oral administration could lead to disorders of the gastrointestinal system with nausea, vomit-
ing, and heartburn.
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3. Parenteral anticoagulants
3.1. Heparins and low-molecular-weight heparins
Heparan sulfate (HS) proteoglycans play vital functions in many biological processes in the 
animal kingdom, and the GAG moiety is essential for these functions. Heparin is synthesized 
from UDP-sugar precursors as a polymer of alternating D-glucuronic acid and N-acetyl-D-
glucosamine residues [44]. Unfractionated heparin (UFH) is a glycosaminoglycan consisting 
of heterogeneous mixture of polysaccharide chains with alternating residues of D-glucosamin 
and uronic acid, glucoronic acid, or iduronic acid, with a molecular weight range of 3000–
30,000 Da. Low-molecular-weight heparins (LWMHs) are fragments of UFH produced by 
controlled enzymatic or chemical depolymerization processes with a mean molecular weight 
of about 5000 Da [45].
3.1.1. Mechanism of action
Both UFH and LMWHs exert their anticoagulant activity by inhibiting thrombin-activated 
conversion of fibrinogen to fibrin [46]: binding of a unique pentasaccharide to antithrombin 
causes a conformational change in antithrombin that accelerates its interaction with thrombin 
and factor Xa by about 1000 times. Binding of the pentasaccharide to antithrombin results 
directly in inhibition of factor Xa, and the pentasaccharide also blocks the activation of factor 
IX and neutralizes factor Xa by activating factor X inhibitor.
3.1.2. Indications
Heparins, and in particular LMWHs, indications comprehend: DVT prophylaxis during peri-
operative or postoperative period of general/orthopedic surgery or in bedridden patients; DVT 
treatment in patients affected by pulmonary embolism; instable angina and non-ST-elevation 
myocardial infarction (NSTEMI) prophylaxis with concomitant use of acetylsalicylic acid; coag-
ulation prevention in patients undergoing dialysis; and symptomatic VTE (proximal DVT and/
or pulmonary embolism) to reduce the recurrence of VTE in patients with solid tumor cancers.
3.1.3. Pharmacokinetics
Heparin is not absorbed orally and therefore is administered parenterally. The two preferred 
routes of administration are continuous intravenous infusion or subcutaneous injection. If 
administered subcutaneously, the dose of heparin should be higher than the usual intrave-
nous dose because subcutaneous administration is associated with reduced bioavailability 
[46]. UFH does not have predictable pharmacokinetics, and it has a small volume of distribu-
tion and a relatively short half-life of about 0.5–1 hour [47]. After injection heparin rapidly 
disappears from blood: the rapid, saturable elimination phase is thought to reflect UFH bind-
ing to vascular endothelial cells, macrophages, and reticuloendothelial cells, where it is inter-
nalized and metabolized into smaller and less sulfated forms [48]. At higher doses, the cellular 
binding sites are saturated, and heparin is cleared predominantly by renal elimination [49]. 
UFH binds also to plasma proteins, changing its pharmacokinetic profile and reducing its 
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anticoagulant activity. Because of the unpredictable anticoagulant response, careful/close 
monitoring is essential, when UFH is given in therapeutic doses [48].
LMWHs do not bind to endothelial cells, macrophages, or reticuloendothelial cells and have 
a 2–4 times longer half-life compared to UFH (3–6 hours). Furthermore, LMWHs have much 
lower affinity for heparin-binding plasma proteins and are mainly removed by nonsaturable 
renal filtration, and thus, their clearance is independent of dose and plasma concentration [50].
3.1.4. Interactions
Heparin use should be avoided in case of concomitant treatment with antiplatelet drugs 
(NSAIDs, diclofenac, piroxicam, ketorolac, nimesulide, and acetylsalicylic acid), anticoagu-
lant agents (warfarin), and glucocorticoids, due to increase in bleeding risk. Furthermore, 
LMWH should not be used in patients with previous heparin-induced thrombocytopenia/
thrombosis (HITT), known hypersensitivity or adverse reaction to LMWH (dalteparin or 
enoxaparin), severe renal impairment, active bleeding, severe or uncontrolled hypertension, 
active peptic ulcerations, hemophilia, and severe liver disease.
3.1.5. Therapy management
Heparin therapy for VTE treatment is typically administered by continuous intravenous infu-
sion, but adjusted dose and fixed dose subcutaneous injections can also be utilized. Obese 
patients clear LMWHs faster than nonobese patients due to hyperfiltration, and their dose 
should be adjusted on total body weight or LMWHs should be substituted with UFHs [51]. 
Therapy monitoring comprehends regular CrCl, platelet count, and antifactor Xa assay 
measurements.
In case of VTE prophylaxis, dosing and duration of LMWHs follow this pattern:
• dalteparin 5000 units subcutaneously once daily for 5–10 days or enoxaparin 40 mg subcu-
taneously once daily for 7–10 days in patients undergoing surgery interventions, who had 
previously VTE or are bedridden;
• dalteparin 2500 units subcutaneously once daily or enoxaparin 20 mg subcutaneously once 
daily in case of renal impairment.
Dosing recommendations for treatment of NSTEMI with enoxaparin take into account renal 
functions and concomitant therapies with antiplatelet agents. In particular:
• enoxaparin 1 mg/kg subcutaneously every 12 hours if CrCl is >50 mL/min;
• enoxaparin 1 mg/kg subcutaneously every 12 hours if CrCl is between 30 and 50 mL/min 
with continue; monitoring of renal function and antifactor Xa levels;
• heparins use is not recommended if CrCl is <30 mL/min.
In case of thrombolysis, anticoagulation is generally given in addition to dual antiplatelet 
therapy at doses adjusted on patient’s age:
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• age < 75 years, 30 mg i.v. bolus immediately prior to thrombolysis followed within 15 min-
utes by 1 mg/kg subcutaneously every 12 hours (each dose should not exceed 100 mg);
• age > 75 years, 0.75 mg/kg subcutaneously every 12 hours (each dose should not exceed 
75 mg in the first two administrations);
• UFHs in patients with CrCl is <30 mL/min.
Intravenous anticoagulation with UFHs in addition to antiplatelet therapy is recommended 
for all patients undergoing primary percutaneous coronary intervention (PCI). Anticoagulant 
therapy is selected according to patient’s ischemic and bleeding risks (70–100 units/kg i.v. 
bolus or 50–70 units/kg i.v. bolus with GPIIb/IIIa inhibitor). Bivalirudin or intravenous enoxa-
parin (0.5 mg/kg i.v.) may be used as alternatives to UFH.
3.1.6. Real-world safety aspects
Safe and effective use of heparin requires maintaining a delicate balance: dosing low enough 
to minimize the risk of bleeding, yet high enough to treat or prevent thrombosis. Achieving a 
therapeutic level of heparin within 24 hours significantly reduces the risk for recurrent VTE 
[52]. However, non-protocol-driven practice achieves this outcome only 40% of the time [53].
Bleeding is the primary untoward effect of heparin. Major bleeding occurs in 1–5% of patients 
treated with intravenous heparin for venous thromboembolism [54]. The incidence of bleed-
ing is somewhat less in patients treated with LMWH for this indication, although the risk of 
bleeding appears to increase with higher total daily doses of heparin.
Heparin-induced thrombocytopenia (platelet count <150,000/mL or a 50% decrease from the 
pre-treatment value) occurs in ~0.5% of medical patients 5–10 days after initiation of therapy 
with heparin [55]. Although the incidence may be lower, thrombocytopenia also occurs with 
LMWHs and fondaparinux and platelet counts should be monitored. Thrombotic complica-
tions that can be life-threatening or lead to amputation occur in about one-half of the affected 
heparin-treated patients and may precede the onset of thrombocytopenia. The incidence of 
heparin-induced thrombocytopenia and thrombosis is higher in surgical patients than in 
medical patients. Women are twice as likely as men to develop this condition.
3.2. Fondaparinux, idraparinux, and idrabiotaparinux
Fondaparinux is a synthetic heparin-like compound that acts as indirect factor Xa inhibitor 
[50]. Idraparinux and idrabiotaparinux are second and third generation pentasaccharides 
derived from fondaparinux.
After subcutaneous administration, fondaparinux is cleared by kidneys and has an elimina-
tion half-life of 17 h in healthy volunteers and 29 h in patients with moderate renal insuf-
ficiency, and therefore, it is contraindicated in patients with severe renal insufficiency. In this 
specific condition, laboratory monitoring is performed with anti-Xa assay, aPTT, and PT [50]. 
Fondaparinux is approved as an alternative for heparin or LMWH in the initial treatment of 
VTE in conjunction with a vitamin K antagonist (VKA) and, in Europe, for ACS in patients for 
whom PCI is not indicated [56].
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Idraparinux has a longer elimination half-time of 120 h after a single administration and accu-
mulation does occur and after more than 6 months of treatment, the elimination half-time is 
increased up to 60 days. It is administered once weekly and is thereby suitable for long-term 
anticoagulation [57]. Idrabiotaparinux was evaluated for treatment of VTE and for stroke pre-
vention in patients with AF, resulting as safe and efficient as idraparinux [58].
3.3. Irudin, lepirudin, desirudin, bivalirudin, and argatroban
Hirudin is a direct thrombin inhibitor (DTI) derived from the salivary secretions of leech 
(Hirudo medicinalis). Lepirudin and desirudin are two forms of recombinant hirudin, struc-
turally identical except for minute differences in the amino-terminus sequence [59]. Unlike 
heparin and others anticoagulants, DTIs do not need antithrombin to perform its anticoagu-
lant action: epirudin and desirudin form a bivalent irreversible complex with thrombin, while 
hirudin binds to both the active site as well as to exosite I on thrombin.
Lepirudin and desirudin have been evaluated for the prevention and treatment of VTE and 
in patients with acute coronary syndrome (ACS). These drugs are generally more effective 
than heparin in prevention of thrombosis but lead to more bleeding complications possibly 
related to their irreversible binding to thrombin [60]. Their indications of use comprehend: 
treatment and prevention of suspected or proven HIT; VTE prophylaxis after hip or knee 
arthroplasty. Lepirudin and desirudin are administered intravenously or subcutaneously and 
have a half-life of 80 and 60–120 minutes, respectively. The excretion is totally renal. Due to 
their narrow therapeutic range, therapy monitoring should be done regularly through aPTT, 
activated clotting time (ACT), and anti-Xa assay evaluation.
Bivalirudin is used in treatment of patients with unstable angina undergoing PCI even if at 
risk of HIT. This is a synthetic analog of hirudin that forms a reversible, high-affinity com-
plex with thrombin [61]. Consequently, bivalirudin has a shorter half-life (25 minutes) and 
is a weaker thrombin inhibitor compared to hirudin, with a potentially larger therapeutic 
window. Its clearance is for 80% enzymatic and for 20% renal. Bivalirudin is now one of the 
preferred drugs for patients undergoing PCI in American and European guidelines, and it has 
become one of the most widely used antithrombotics in the USA for PCI [62].
Argatroban is a small, univalent competitive inhibitor of thrombin. It binds selectively and revers-
ibly to the active site of thrombin and has a short elimination half-life of 50 min through hepatobi-
liary clearance. Since it is metabolized in the liver, it should be used with caution in patients with 
liver failure. Argatroban has been approved for the prevention and treatment of VTE in patients 
with HIT [46, 47] and for patients with (a history of) HIT who need to undergo PCI [46, 63].
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